National Cancer Institute (NCI): Sarcoma, Alveolar Soft Part trials
The registry lists 11 Sarcoma, Alveolar Soft Part studies with National Cancer Institute (NCI) as lead sponsor. 2 are open to participants now and 7 have results posted.
Phase 1 2Phase 2 9Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1
- Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialRecruitingNCT05333458Phase 2
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/3Results posted
- Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 2Results posted
- Sunitinib or Cediranib for Alveolar Soft Part SarcomaCompletedNCT01391962Phase 2Results posted
- Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1/2Results posted
- Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part SarcomaCompletedNCT00942877Phase 2Results posted
- Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue SarcomaCompletedNCT00112463Phase 2Results posted
- Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaActive, not recruitingNCT03141684Phase 2
- Collection of Alveolar Soft Part Sarcoma and Blood Specimens for ResearchCompletedNCT00340353